Novartis Ag (NVS) Payables (2009 - 2025)

Novartis Ag has disclosed Payables across 14 years of filings, most recently posting $5.1 billion for Q4 2025.

• Payables for Q4 2025 came in at $5.1 billion, down 1.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.1 billion (down 1.46% YoY), and the FY2025 annual result was $5.1 billion, down 1.46% from the prior year.
• Payables came in at $5.1 billion for Q4 2025 at Novartis Ag, up from $4.5 billion in the prior quarter.
• In the past five years, Payables ranged from a high of $6.5 billion in Q4 2021 to a low of $4.1 billion in Q2 2024.
• The 5-year median for Payables is $5.2 billion (2024), against an average of $5.2 billion.
• Across the five-year window, Payables dropped 22.5% in 2024 and advanced 8.68% in 2025, its largest moves.
• Novartis Ag's Payables stood at $6.5 billion in 2021, then retreated by 6.87% to $6.0 billion in 2022, then slipped by 7.64% to $5.6 billion in 2023, then fell by 6.05% to $5.2 billion in 2024, then dropped by 1.46% to $5.1 billion in 2025.
• The last three Payables figures came in at $5.1 billion (Q4 2025), $4.5 billion (Q2 2025), and $5.2 billion (Q4 2024), per Business Quant data.